Royalty Pharma plc (RPRX) / ResearchSEC submissions · retrieved 2026-10-20 · 8029 issuers; up to 32 recent company reports and 8 ownership-change filings per issuer
2026-10-05 2026-09-30 2026-09-30 2026-09-24 2026-08-19 2026-08-17 2026-08-07 2026-08-07 2026-08-05 2026-08-05 2026-06-04 2026-05-28 2026-05-06 2026-05-06 2026-04-13 2026-04-10 2026-02-11 2026-02-11 2025-12-22 2025-12-22 2025-11-05 2025-11-05 2025-09-16 2025-08-13 2025-08-06 2025-08-06 2025-07-17 2025-05-19 8-K · Current reportReport date 2025-05-16 · 0000950103-25-006186 · Items 1.01,2.01,2.03,5.02,5.03,9.01
2025-05-12 2025-05-08 2025-05-08 2025-04-11 2025-04-10 2025-02-12 2025-02-11 2025-01-13 2025-01-10 2025-01-10 2024-12-31 2024-11-08 SEC insider transactions · retrieved 2026-10-15 · 2026 Q3: filings in this completed quarter; not a live transaction feed
Purchases and sales include open-market or private transactions. Grants, exercises and tax withholding are shown separately. Amendments and joint reports can overlap; rows are not a net-buying score. Prices retain the filing's units; consult its footnotes.
Transaction rows by code · counts, not monetary totals Purchase: 0 transaction rows 0 P Sale: 11 transaction rows 11 S Grant / award: 5 transaction rows 5 A Exercise / conversion: 0 transaction rows 0 M Tax / exercise payment: 0 transaction rows 0 F Gift: 4 transaction rows 4 G P · Purchase S · Sale A · Grant / award M · Exercise / conversion F · Tax / exercise payment G · Gift
20 matching transaction rows.
Transaction / filed Reporting owner Type Security Shares Reported price 2026-09-30 2026-09-30
Bassler Bonnie L A · Grant / awardAcquired
Class A Ordinary Shares 642.0 58.41 2026-09-28 2026-09-30
Urist Marshall10b5-1 checkbox reported
S · SaleDisposed
Class A Ordinary Shares 4126.0 57.88 2026-09-22 2026-09-24
Hite Christopher10b5-1 checkbox reported
S · SaleDisposed
Class A Ordinary Shares 96073.0 58.51 2026-09-22 2026-09-24
Hite Christopher10b5-1 checkbox reported
S · SaleDisposed
Class A Ordinary Shares 3927.0 58.93 2026-08-19 2026-08-19
Hite Christopher10b5-1 checkbox reported
G · GiftDisposed
Class A Ordinary Shares 16800.0 0.0 2026-08-18 2026-08-19
Hite Christopher10b5-1 checkbox reported
S · SaleDisposed
Class A Ordinary Shares 100000.0 59.97 2026-08-13 2026-08-17
Coyne Terrance P.10b5-1 checkbox reported
S · SaleDisposed
Class A Ordinary Shares 9230.0 58.59 2026-08-13 2026-08-17
Coyne Terrance P.10b5-1 checkbox reported
S · SaleDisposed
Class A Ordinary Shares 1772.0 59.14 2026-08-07 2026-08-07
Urist Marshall G · GiftDisposed
LP interests in RPI US Partners 2019, LPDerivative security
3000.0 0.0 2026-08-07 2026-08-07
Coyne Terrance P. G · GiftDisposed
Class E Ordinary SharesDerivative security
18500.0 0.0 2026-08-07 2026-08-07
Legorreta Pablo G. G · GiftDisposed
LP interests in RPI US Partners 2019, LPDerivative security
30000.0 0.0 2026-08-05 2026-08-07
Urist Marshall A · Grant / awardAcquired
Class A Ordinary Shares 8252.0 0.0 2026-08-05 2026-08-07
Coyne Terrance P. A · Grant / awardAcquired
Class A Ordinary Shares 11002.0 0.0 2026-08-05 2026-08-07
Hite Christopher A · Grant / awardAcquired
Class A Ordinary Shares 11002.0 0.0 2026-08-05 2026-08-07
Legorreta Pablo G. A · Grant / awardAcquired
Class A Ordinary Shares 65216.0 0.0 2026-07-01 2026-07-02
Urist Marshall10b5-1 checkbox reported
S · SaleDisposed
Class A Ordinary Shares 9099.0 55.88 2026-06-30 2026-07-02
Hite Christopher10b5-1 checkbox reported
S · SaleDisposed
Class A Ordinary Shares 2554.0 57.1 2026-06-30 2026-07-02
Hite Christopher10b5-1 checkbox reported
S · SaleDisposed
Class A Ordinary Shares 97446.0 56.5 2026-06-30 2026-07-02
Hite Christopher10b5-1 checkbox reported
S · SaleDisposed
Class A Ordinary Shares 600.0 57.09 2026-06-30 2026-07-02
Hite Christopher10b5-1 checkbox reported
S · SaleDisposed
Class A Ordinary Shares 29400.0 56.44
Identity & relationships Wikidata structured data · retrieved 2026-10-15 · 1663 unambiguous CIK-linked entities; coverage is incomplete
These are sourced identity and relationship claims, with incomplete coverage. Headquarters locations do not describe sales, assets or operating exposure.
SEC issuer · 0001802768 Royalty Pharma plc
No parent relationship is available in this import; this is not proof of independence.
No verified LEI join available.
GLEIF legal entity reference data · retrieved 2026-10-15 · 1199 checked identities; 0 unavailable records
Search names and former names Revenue in constant purchasing power USD revenue expressed in 2026-09 consumer-price dollars. Each annual period uses a CPI-U average weighted by the days in its actual reporting interval. This is a purchasing-power comparison, not a company-specific price or volume measure.
Year ended Reported USD revenue CPI-adjusted USD revenue 2024-12-31 $2.26B $2.43B 2023-12-31 $2.35B $2.60B 2022-12-31 $2.24B $2.58B 2021-12-31 $2.29B $2.85B 2020-12-31 $2.12B $2.76B 2019-12-31 $1.81B $2.39B 2018-12-31 $1.79B $2.41B
Bureau of Labor Statistics · retrieved 2026-10-20 · 9 selected series; gaps remain missing
Explore the CPI history ↗